H.C. Wainwright lowered the firm’s price target on Coherus Biosciences to $11 from $13 and keeps a Buy rating on the shares post the Q4 report. The analyst cites the company’s pipeline updates for the target drop. Following the close of the agreement with Sandoz to divest the Cimerli franchise, the firm removed the product from its valuation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CHRS:
- Coherus Biosciences reports Q4 EPS (62c), consensus (12c)
- Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
- Coherus BioSciences options imply 21.5% move in share price post-earnings
- Options Volatility and Implied Earnings Moves Today, March 13, 2024
- Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
